Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Der US-Markt hat eine robuste Leistung gezeigt, mit einem Anstieg von 2,6% innerhalb der letzten Woche und 26% im Vergangenen Jahr. In diesem aufblühenden Umfeld können Investoren durch die Identifizierung von Aktien, die möglicherweise unter ihrem Schätzwert gehandelt werden, Chancen für Wachstum nutzen.

Die folgenden 3 Aktien könnten möglicherweise unter ihrem Schätzwert gehandelt werden: Western Digital (WDC) - 48,5% Discount Tuniu (TOUR) - 50% Discount Sea (SE) - 48,3% Discount ... und weitere 10 Aktien.

Cohu ist eine Aktie, die möglicherweise unter ihrem Schätzwert gehandelt wird. Sie hat einen Marktanteil von etwa 2,34 Milliarden US-Dollar und erwirtschaftet ein Umsatzvolumen von 481,28 Millionen US-Dollar.

BlackSky Technology ist eine weitere Aktie, die möglicherweise unter ihrem Schätzwert gehandelt wird. Sie hat einen Marktanteil von etwa 1,46 Milliarden US-Dollar und erwirtschaftet ein Umsatzvolumen von 97,81 Millionen US-Dollar.

Beazer Homes USA ist eine weitere Aktie, die möglicherweise unter ihrem Schätzwert gehandelt wird. Sie hat einen Marktanteil von etwa 496,06 Millionen US-Dollar und erwirtschaftet ein Umsatzvolumen von 545,18 Millionen US-Dollar.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Im letzten Woche ist der US-Markt um 2,6% gestiegen, was zu einem beeindruckenden 26%-Anstieg im Vergangenen Jahr geführt hat. In diesem prosperierenden Umfeld können Investoren durch die Identifizierung von Aktien, die möglicherweise unter ihrem geschätzten Wert gehandelt werden, potenzielle Wachstumsmöglichkeiten und Wertsteigerungen nutzen.

Top 10 Aktien, die aufgrund von Cash-Flows in den USA als unterbewertet gelten

Name Aktueller Preis Schätzwert (Est) Discount (Est) Western Digital (WDC) $515.83 $1001.92 48,5% Tuniu (TOUR) $5.71 $11.41 50% Sea (SE) $84.87 $164.01 48,3% Rayonier (RYN) $20.31 $40.03 49,3% MercadoLibre (MELI) $1557.30 $3035.20 48,7% Lazard (LAZ) $45.98 $89.64 48,7% Kodiak Gas Services (KGS) $75.52 $150.36 49,8% Janus Living (JAN) $27.23 $54.11 49,7% iRhythm Holdings (IRTC) $116.84 $233.64 50% CVR Energy (CVI) $34.88 $67.50 48,3%

Klicken Sie hier, um die vollständige Liste von 141 Aktien aus unserem Screener "Undervalued US Stocks Based On Cash Flows" zu sehen.

Hier ist ein Blick auf einige der Auswahlmöglichkeiten aus dem Screener.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Frank Sands hat kürzlich das 13F-Formular für das erste Quartal 2026 eingereicht. Darin sind seine Investitionsentscheidungen während dieser Zeit enthalten. Frank M. Sands, Jr., CFA ist der CEO und CIO von Sands Capital Management, einem Investmentmanagementunternehmen, das auf die Investition in Qualitätswachstumsunternehmen weltweit fokussiert ist. Er verbringt den Großteil seiner Zeit damit, sich mit Investitionsforschung und Entscheidungen sowie Geschäftsstrategien zu beschäftigen. Sands Capital Management wurde von seinem Vater, Frank M. Sands, Sr., 1992 gegründet. Frank Sands (Trades, Portfolio), Jr. trat der Firma im Jahr 2000 bei, nachdem er sechs Jahre als Researchanalyst und Portfoliomanager für Fayez Sarofim & Co., ein institutionelles Investmentmanagementunternehmen in Houston, Texas, gearbeitet hatte. Seit seiner Aufnahme bei Sands Capital Management hat die Firma weiterhin starke Investitionsresultate für ihre Kunden erzielt. Sands Jr. besitzt einen BA von Washington & Lee University, einen MS von Johns Hopkins University und einen MBA von der Darden School an der University of Virginia. Sands Capital glaubt, dass sich Aktienpreise im Laufe der Zeit spiegeln, was die Gewinnwachstumsrate ihrer zugrunde liegenden Unternehmen ist. Seine Mannschaft ist darauf konzentriert, die relativ kleine Anzahl von wirklich außergewöhnlichen Wachstumsunternehmen zu identifizieren, die sie für viele Jahre besitzen werden. Die Firma hat zwei Hauptkonzentrierte Wachstumskonzepte: Select Growth, das sich auf schnell wachsende innovative Unternehmen konzentriert, und Global Growth, das sich auf schnell wachsende Unternehmen weltweit konzentriert.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Okay, here’s a 600-word summary of the text, followed by the German translation:

Summary (600 Words)

The US stock market is currently exhibiting strong growth, with a recent 1.9% weekly increase and a significant 24% year-over-year rise. Furthermore, analysts predict annual earnings growth of 15% over the next few years, presenting attractive opportunities for investors. The core strategy highlighted here is identifying stocks trading below their intrinsic value, often referred to as “undervalued” assets. This approach focuses on finding companies where the market price doesn't accurately reflect the underlying value determined by their cash flow potential.

The article presents a selection of 10 US stocks identified using a “Cash Flows” screener, all of which are considered undervalued based on discounted cash flow analysis. These stocks were evaluated based on their current price, estimated fair value, and the resulting discount. The analysis suggests that investors could potentially capitalize on these discrepancies.

Several companies are highlighted, including:

• Roku (ROKU): Trading at $97.66, Roku’s estimated fair value is $191.69, representing a 49.1% discount. The company’s streaming platform is experiencing growth, and despite recent challenges (insider selling, margin declines), projected earnings growth of 31.5% annually is a positive indicator.

• Datadog (DDOG): A cloud observability platform, Datadog is priced at $120.36, with an estimated fair value of $179.46 – a 32.9% discount. While facing challenges such as declining profit margins, the company’s projected earnings growth of 31.5% annually remains encouraging.

• Coupang (CPNG): A South Korean e-commerce giant, Coupang is trading at $18.95 with an estimated fair value of $28.61, demonstrating a 33.8% discount. Despite revenue growth lagging the market average, its strong earnings growth potential (36.1% annually) is a key attraction.

• Northwest Bancshares (NWBI), iRhythm Holdings (IRTC), Investar Holding (ISTR), Fluence Energy (FLNC), Ellington Financial (EFC), Earth Science Tech (ETST), DNOW, Clear Secure (YOU): These stocks also demonstrate significant discounts based on cash flow analysis, suggesting potential upside for investors willing to take on the risk.

The article emphasizes that these valuations are based on discounted cash flow (DCF) models, which estimate a company’s value by considering the present value of its future cash flows. This method often identifies companies that the market has overlooked, potentially leading to returns.

Furthermore, the article suggests strategies for expanding your investment horizons: exploring high-performing small-cap companies, dividend payers for stable income, and companies with strong growth potential based on analyst and management forecasts. The “Simply Wall St” platform is highlighted as a tool to access this information and manage a portfolio.

Crucially, the article disclaims that its analysis is based on historical data and analyst forecasts and is not financial advice. It stresses the importance of considering individual investment objectives and financial situations before making decisions. It also notes that the analysis may not reflect the most recent company announcements.

German Translation (Approximately 600 Words)

Zusammenfassung des Textes (600 Wörter)

Der US-Aktienmarkt verzeichnete zuletzt einen positiven Trend, mit einer Steigerung von 1,9 % in der letzten Woche und einer signifikanten Erhöhung von 24 % im vergangenen Jahr. Darüber hinaus prognostizieren Analysten ein jährliches Gewinnwachstum von 15 % in den kommenden Jahren, was attraktive Möglichkeiten für Investoren bietet. Die hier hervorgehobene Strategie konzentriert sich auf die Identifizierung von Aktien, die unter ihrem intrinsischen Wert gehandelt werden – also “unterbewerteten” Vermögenswerten. Dieser Ansatz zielt darauf ab, Unternehmen zu finden, bei denen der Marktpreis den zugrunde liegenden Wert, der durch deren Cashflow-Potenzial bestimmt wird, nicht korrekt widerspiegelt.

Der Artikel präsentiert eine Auswahl von 10 US-Aktien, die mithilfe eines “Cash Flows” Screener identifiziert wurden, alle mit einem niedrigen Preis-Leistungs-Verhältnis aufgrund einer Bewertung anhand des diskontierten Cashflows. Diese Aktien wurden anhand ihres aktuellen Preises, des geschätzten fairen Werts und der daraus resultierenden Diskrepanz bewertet. Die Analyse deutet darauf hin, dass Investoren potenziell von diesen Ungleichgewichten profitieren könnten.

Mehrere Unternehmen werden hervorgehoben, darunter:

• Roku (ROKU): Mit einem Preis von 97,66 US-Dollar handelt sich Roku mit einem geschätzten fairen Wert von 191,69 US-Dollar um 49,1 % unter dem Wert. Die Streaming-Plattform des Unternehmens wächst, und trotz jüngster Herausforderungen (Insider-Verkäufe, Margenrückgänge) ist das prognostizierte Gewinnwachstum von 31,5 % jährlich ein ermutigendes Zeichen.

• Datadog (DDOG): Eine Cloud-Observability-Plattform, Datadog wird zu 120,36 US-Dollar gehandelt, mit einem geschätzten fairen Wert von 179,46 US-Dollar – einem Rückgang von 32,9 %. Obwohl das Unternehmen mit sinkenden Gewinnmargen konfrontiert ist, bleibt das prognostizierte Gewinnwachstum von 31,5 % jährlich ermutigend.

• Coupang (CPNG): Ein südkoreanischer E-Commerce-Riese, Coupang wird zu 18,95 US-Dollar gehandelt, mit einem geschätzten fairen Wert von 28,61 US-Dollar, was einen Rückgang von 33,8 % darstellt. Trotz eines Umsatzwachstums, das hinter dem Marktdurchschnitt liegt, ist das starke Gewinnwachstumspotenzial (36,1 % jährlich) ein wichtiges Verkaufsargument.

• Northwest Bancshares (NWBI), iRhythm Holdings (IRTC), Investar Holding (ISTR), Fluence Energy (FLNC), Ellington Financial (EFC), Earth Science Tech (ETST), DNOW, Clear Secure (YOU): Diese Aktien zeigen ebenfalls erhebliche Rabatte basierend auf der Cashflow-Analyse, was potenzielle Gewinne für Investoren signalisiert, die bereit sind, das Risiko einzugehen.

Der Artikel betont, dass diese Bewertungen auf DCF-Modellen (discounted cash flow) beruhen, die den Wert eines Unternehmens anhand des Barwerts seiner zukünftigen Cashflows schätzen. Diese Methode identifiziert häufig Unternehmen, die der Markt übersehen hat, was potenziell zu Renditen führt.

Darüber hinaus schlägt der Artikel vor, Ihren Anlagehorizont zu erweitern: die Erforschung von Unternehmen mit hoher Leistung im Small-Cap-Bereich, Dividendenzahlungen für stabilen Einkommen und Unternehmen mit starkem Wachstumspotenzial basierend auf Analysen und Managementprognosen. Die “Simply Wall St” Plattform wird als Werkzeug hervorgehoben, um diese Informationen zu erhalten und ein Portfolio zu verwalten.

Vor allem betont der Artikel, dass seine Analyse auf historischen Daten und Analystenprognosen basiert und keine Finanzberatung darstellt. Es wird die Bedeutung der Berücksichtigung individueller Anlageziele und finanzieller Situationen vor jeder Entscheidung hervorgehoben. Es wird auch darauf hingewiesen, dass die Analyse möglicherweise nicht die neuesten Unternehmensankündigungen widerspiegelt.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Okay, here’s a 600-word summary of the text, followed by a German translation:

Summary (600 words)

iRhythm Holdings (IRTC) is a leading provider of ambulatory cardiac monitoring (ACM) technology, operating a digital diagnostics platform utilizing wearable biosensors (Zio) and AI. The company is well-positioned for continued growth, driven by strong volume growth across various channels, expansion into primary care, and deep integration with Electronic Health Record (EHR) systems. Despite some headwinds, the company’s innovative approach and strategic investments suggest a positive outlook.

Key Positives:

• Robust Growth Momentum: iRhythm has demonstrated impressive year-over-year revenue growth (over 20% in recent quarters), fueled by increased volume and the adoption of its Zio platform. This growth is diversified across cardiology, primary care, and international markets.
• Strategic Expansion into Primary Care: The company's successful move into primary care, serving approximately 40,000 physicians, expands its addressable market and aligns with value-based healthcare trends. This shift is supported by the ability to detect arrhythmias earlier.
• EHR Integration: iRhythm’s deep integration with EHR systems is a significant competitive advantage, improving workflow efficiency, prescription consistency, and customer retention. More than half of their volume now flows through EHR-integrated accounts.
• AI and Data Advantage: The company’s substantial ECG dataset (over 3 billion hours of recordings) and advanced AI algorithms, validated through clinical trials (CAMELOT & AVALON), create a strong “moat” – a barrier to entry for competitors. Studies show superior diagnostic yields and reduced healthcare utilization using the Zio platform.
• Predictive Healthcare Initiative: A collaboration with Lucem Health leverages AI to identify at-risk patients, moving iRhythm toward a digital health intelligence platform.

Challenges and Risks:

• Reimbursement Pressures: iRhythm faces ongoing challenges with reimbursement rates in international markets, particularly in Japan and Europe, where current rates are insufficient to fully capture the value of the Zio platform. The company needs to demonstrate superior clinical outcomes to secure better pricing.
• Channel Expansion Reliance: The company's growth is dependent on successful expansion into new channels, particularly within primary care. Any slowdown in adoption or payer alignment could negatively impact growth.
• Competitive Pressure: iRhythm operates in a competitive market with traditional Holter monitoring, telemetry systems, and emerging wearable technologies. Rapid technological advancements could lead to lower prices and erosion of market share.
• Regulatory Uncertainty: Cost-effectiveness scrutiny from Medicare and commercial insurers could hinder adoption.

Financial Performance & Outlook:

iRhythm has demonstrated strong earnings performance, exceeding estimates in most quarters. The company projects revenues of $870-$880 million for 2026, reflecting continued volume-led growth. The Zacks Rank #3 (Hold) reflects the company's strong fundamentals, though the S&P 500 has outperformed.

German Translation (approximately 600 words):

Zusammenfassung (600 Wörter)

iRhythm Holdings (IRTC) ist ein führender Anbieter von ambulatorischer kardialer Überwachung (ACM) – Technologie, der eine digitale Diagnostikplattform mit tragbaren Biosensoren (Zio) und KI betreibt. Das Unternehmen ist aufgrund von starkem Umsatzwachstum über verschiedene Kanäle, der Expansion in die allgemeine medizinische Versorgung und der tiefgreifenden Integration in elektronische Patientenakte (EHR)-Systeme gut positioniert für weiteres Wachstum. Trotz einiger Herausforderungen deutet der innovative Ansatz und die strategischen Investitionen des Unternehmens auf eine positive Perspektive hin.

Wichtige Positive Aspekte:

• Robustes Wachstumsmomentum: iRhythm hat beeindruckendes Umsatzwachstum im Jahresvergleich (über 20 % in den letzten Quartalen) gezeigt, angetrieben durch eine erhöhte Volumen und die Einführung der Zio-Plattform. Dieses Wachstum ist diversifiziert über Kardiologie, allgemeine medizinische Versorgung und internationale Märkte.
• Strategische Expansion in die allgemeine medizinische Versorgung: Der erfolgreiche Schritt des Unternehmens in die allgemeine medizinische Versorgung, der rund 40.000 Ärzte bedient, erweitert den adressierbaren Markt und stimmt mit Trends im Bereich der Wertorientierten Gesundheitsversorgung überein. Dieser Wandel wird durch die Fähigkeit unterstützt, Herzrhythmusstörungen früher zu erkennen.
• EHR-Integration: Die tiefe Integration von iRhythm in EHR-Systeme ist ein bedeutender Wettbewerbsvorteil, der die Arbeitsabläufe verbessert, die Verschreibungskonsistenz erhöht und die Kundentreue stärkt. Über die Hälfte des Umsatzes fließt jetzt über EHR-integrierte Konten.
• KI und Datenvorteil: Das Unternehmen verfügt über einen erheblichen ECG-Datensatz (über 3 Milliarden Stunden Aufzeichnungen) und fortschrittliche KI-Algorithmen, die durch klinische Studien (CAMELOT & AVALON) validiert wurden, wodurch ein starker "Mauer" geschaffen wird – eine Eintrittsbarriere für Wettbewerber. Studien zeigen höhere diagnostische Erträge und geringere Gesundheitsausgaben mithilfe der Zio-Plattform.
• Initiative für prädiktive Gesundheitsversorgung: Eine Zusammenarbeit mit Lucem Health nutzt KI, um Patienten zu identifizieren, die im Risikobereich liegen, und verschiebt iRhythm in Richtung einer digitalen Gesundheitsintelligenzplattform.

Herausforderungen und Risiken:

• Abrechnungspressuren: iRhythm steht weiterhin vor Herausforderungen bei den Abrechnungssätzen in internationalen Märkten, insbesondere in Japan und Europa, wo die derzeitigen Sätze unzureichend sind, um den Wert der Zio-Plattform vollständig zu erfassen. Das Unternehmen muss nachweisen, dass es bessere klinische Ergebnisse erzielt, um bessere Preise zu erhalten.
• Abhängigkeit von der Kanalexpansion: Das Wachstum des Unternehmens hängt von einer erfolgreichen Expansion in neue Kanäle ab, insbesondere in der allgemeinen medizinischen Versorgung. Eine Verlangsamung der Akzeptanz oder der Abgleichsvereinbarungen mit Kostenträgern könnte das Wachstumspotenzial negativ beeinflussen.
• Wettbewerbsdruck: iRhythm betreibt in einem wettbewerbsintensiven Markt mit traditioneller Holter-Überwachung, Telemetriesystemen und neuen tragbaren Technologien. Schnelle technologische Fortschritte könnten zu niedrigeren Preisen und einem Verlust von Marktanteilen führen.
• Regulatorische Unsicherheiten: Die Kosten-Nutzen-Bewertungen von Medicare und kommerziellen Kostenträgern könnten die Akzeptanz behindern.

Finanzielle Leistung und Ausblick:

iRhythm hat eine starke Gewinnentwicklung gezeigt und die Schätzungen in den meisten Quartalen übertroffen. Das Unternehmen prognostiziert Umsätze von 870 bis 880 Millionen US-Dollar für 2026 und spiegelt so das kontinuierliche volumenbasierte Wachstum wider. Der Zacks Rank #3 (Hold) spiegelt die starken Fundamentaldaten des Unternehmens wider, obwohl der S&P 500 besser abgeschnitten hat.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Over the last 7 days, the United States market has remained flat, yet it is up 16% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying stocks that are trading at a discount can offer potential opportunities for investors seeking value in a growing market.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Roku (ROKU) $94.62 $187.39 49.5% iRhythm Holdings (IRTC) $118.02 $230.66 48.8% Hasbro (HAS) $93.60 $185.05 49.4% Ellington Financial (EFC) $11.85 $23.19 48.9% Dime Community Bancshares (DCOM) $33.82 $66.58 49.2% CuriosityStream (CURI) $2.96 $5.73 48.4% Crexendo (CXDO) $6.17 $11.93 48.3% Bar Harbor Bankshares (BHB) $32.45 $63.66 49% Andersen Group (ANDG) $27.20 $53.13 48.8% Allot (ALLT) $6.66 $13.22 49.6%

Click here to see the full list of 156 stocks from our Undervalued US Stocks Based On Cash Flows screener.

We're going to check out a few of the best picks from our screener tool.

MercadoLibre

Overview: MercadoLibre, Inc. operates online commerce platforms in Brazil, Mexico, Argentina, and internationally with a market cap of approximately $82.09 billion.

Operations: The company generates revenue of $28.89 billion from its Internet Software & Services segment.

Estimated Discount To Fair Value: 24.1%

MercadoLibre is trading at 24.1% below its estimated fair value and significantly undervalued based on discounted cash flow, with a stock price below the future cash flow estimate of US$2,277.18. Despite high debt levels, earnings grew by 4.5% last year and are expected to grow significantly over the next three years, outpacing the US market average. Recent expansion plans include a US$3.4 billion investment in Argentina for logistics and fintech growth in 2026.

Our growth report here indicates MercadoLibre may be poised for an improving outlook. Click to explore a detailed breakdown of our findings in MercadoLibre's balance sheet health report.MELI Discounted Cash Flow as at Apr 2026

Palo Alto Networks

Overview: Palo Alto Networks, Inc. offers cybersecurity solutions across various global regions and has a market cap of approximately $125.18 billion.

Operations: The company's revenue primarily comes from its Security Software & Services segment, which generated $9.89 billion.

Estimated Discount To Fair Value: 12.6%

Palo Alto Networks is trading at 12.6% below its fair value estimate and slightly undervalued based on discounted cash flow, with a stock price of US$160.32 compared to the future cash flow value estimate of US$183.43. Despite recent shareholder dilution, earnings have grown significantly over the past five years and are projected to continue growing faster than the broader US market, driven by strategic product launches like Prisma AIRS 3.0 and expanded buyback plans totaling $5.11 billion.

Story Continues

Our earnings growth report unveils the potential for significant increases in Palo Alto Networks' future results. Click here to discover the nuances of Palo Alto Networks with our detailed financial health report.PANW Discounted Cash Flow as at Apr 2026

Eli Lilly

Overview: Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products globally with a market cap of $793.37 billion.

Operations: The company generates revenue of $65.18 billion from its pharmaceutical products across various regions including the United States, Europe, China, and Japan.

Estimated Discount To Fair Value: 36.2%

Eli Lilly is trading at 36.2% below its estimated fair value, with a stock price of US$919.77 compared to the future cash flow value estimate of US$1441.72, suggesting it may be undervalued based on cash flows. Recent clinical trials, such as the TOGETHER-PsA study, show promising results for combined therapies addressing psoriatic arthritis and obesity, potentially enhancing revenue streams. Despite high debt levels, earnings have grown significantly over the past year and are forecasted to grow faster than the broader US market.

Upon reviewing our latest growth report, Eli Lilly's projected financial performance appears quite optimistic. Dive into the specifics of Eli Lilly here with our thorough financial health report.LLY Discounted Cash Flow as at Apr 2026

Taking Advantage

Explore the 156 names from our Undervalued US Stocks Based On Cash Flows screener here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Ready For A Different Approach?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include MELIPANW and LLY.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including Insulet (NASDAQ:PODD) and its peers.

Patient monitoring companies within the healthcare equipment industry offer devices and technologies that track chronic conditions and support real-time health management, such as continuous glucose monitors (CGMs) and sleep apnea machines. These businesses benefit from recurring revenue from consumables and software subscriptions tied to device sales (razor, razor blade model). The rising prevalence of chronic diseases like diabetes and respiratory disorders due to an aging population as well as growing adoption of digitization are good for the industry. However, these companies face challenges from high R&D costs and reliance on regulatory approvals. Looking ahead, the sector is positioned for growth due to tailwinds like the rising burden of chronic diseases from an aging population, the shift toward value-based care, and increased adoption of digital health solutions. Innovations in AI and machine learning are expected to enhance device accuracy and functionality, improving patient outcomes and driving demand. However, there are headwinds such as pricing pressures as healthcare costs are a key focus, especially in the US. An evolving regulatory landscape and competition from more tech-forward new entrants could present additional challenges.

The 4 patient monitoring stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 1.9% while next quarter’s revenue guidance was 1.9% below.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 16% since the latest earnings results.

Insulet (NASDAQ:PODD)

Revolutionizing diabetes care with its tubeless "Pod" technology, Insulet (NASDAQ:PODD) develops and manufactures innovative insulin delivery systems for people with diabetes, primarily through its Omnipod product line.

Insulet reported revenues of $783.8 million, up 31.2% year on year. This print exceeded analysts’ expectations by 2%. Overall, it was a strong quarter for the company with an impressive beat of analysts’ revenue and EPS estimates.

“We ended the year with another excellent quarter, demonstrating the power of our business model, the strength of our technology, and the disciplined execution of our team,” said Ashley McEvoy, President and CEO.Insulet Total Revenue

Insulet scored the fastest revenue growth of the whole group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 16% since reporting and currently trades at $206.93.

Story Continues

Read why we think that Insulet is one of the best patient monitoring stocks, our full report is free.

Best Q4: iRhythm (NASDAQ:IRTC)

Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ:IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders.

iRhythm reported revenues of $208.9 million, up 27.1% year on year, outperforming analysts’ expectations by 3.4%. The business had a very strong quarter with a beat of analysts’ EPS and revenue estimates.iRhythm Total Revenue

iRhythm delivered the biggest analyst estimates beat and highest full-year guidance raise among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 28.1% since reporting. It currently trades at $114.25.

Is now the time to buy iRhythm? Access our full analysis of the earnings results here, it’s free.

Slowest Q4: DexCom (NASDAQ:DXCM)

Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks.

DexCom reported revenues of $1.26 billion, up 13.1% year on year, exceeding analysts’ expectations by 0.8%. Still, it was a mixed quarter as it posted full-year revenue guidance meeting analysts’ expectations.

DexCom delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 4.9% since the results and currently trades at $61.86.

Read our full analysis of DexCom’s results here.

ResMed (NYSE:RMD)

Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE:RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use.

ResMed reported revenues of $1.42 billion, up 11% year on year. This number surpassed analysts’ expectations by 1.6%. Overall, it was a strong quarter as it also logged a decent beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

ResMed had the slowest revenue growth among its peers. The stock is down 15% since reporting and currently trades at $219.04.

Read our full, actionable report on ResMed here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

StockStory’s analyst team — all seasoned professional investors — uses quantitative analysis and automation to deliver market-beating insights faster and with higher quality.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Over the last 7 days, the United States market has experienced a 1.9% decline; however, it remains up by 15% over the past year with earnings projected to grow by 15% annually. In this context, identifying stocks that are trading at significant discounts can present valuable opportunities for investors seeking to capitalize on potential growth while navigating current market fluctuations.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Metropolitan Bank Holding (MCB) $80.65 $156.56 48.5% iRhythm Holdings (IRTC) $118.10 $230.91 48.9% Intapp (INTA) $24.68 $48.87 49.5% Hamilton Lane (HLNE) $94.77 $187.65 49.5% DNOW (DNOW) $12.25 $24.26 49.5% Crexendo (CXDO) $6.16 $11.90 48.2% Bridgewater Bancshares (BWB) $17.44 $33.82 48.4% Bar Harbor Bankshares (BHB) $31.81 $63.52 49.9% Alnylam Pharmaceuticals (ALNY) $317.36 $618.07 48.7% Alkami Technology (ALKT) $15.25 $30.05 49.2%

Click here to see the full list of 155 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's uncover some gems from our specialized screener.

Golar LNG

Overview: Golar LNG Limited designs, converts, owns, and operates marine infrastructure for the liquefaction of natural gas, with a market cap of $5.60 billion.

Operations: Golar LNG Limited's revenue primarily comes from its First Floating Liquefaction Natural Gas (FLNG) segment, generating $366.72 million.

Estimated Discount To Fair Value: 45.1%

Golar LNG appears undervalued, trading at US$55.03, significantly below its estimated future cash flow value of US$100.33. Despite debt concerns, the company shows strong revenue and earnings growth forecasts, with earnings expected to grow 34.9% annually over three years—outpacing the US market's 15.5%. Recent strategic reviews aim to enhance shareholder value further by exploring potential mergers or asset sales, indicating a proactive approach to leveraging its FLNG technology and growth pipeline.

Our expertly prepared growth report on Golar LNG implies its future financial outlook may be stronger than recent results. Get an in-depth perspective on Golar LNG's balance sheet by reading our health report here.GLNG Discounted Cash Flow as at Mar 2026

Ramaco Resources

Overview: Ramaco Resources, Inc. is involved in the development, operation, and sale of metallurgical coal with a market cap of $992.43 million.

Operations: The company generates revenue primarily through its metallurgical coal segment, which accounted for $536.62 million.

Estimated Discount To Fair Value: 22.6%

Ramaco Resources is trading at US$15.56, below its estimated future cash flow value of US$20.09, suggesting it may be undervalued. However, the company reported a net loss of US$51.45 million for 2025 amidst declining sales and legal challenges related to alleged misleading statements about its Brook Mine project. Despite these setbacks, Ramaco's revenue growth forecast outpaces the broader market, and it has secured increased financial flexibility with expanded credit facilities totaling nearly $1 billion.

Story Continues

In light of our recent growth report, it seems possible that Ramaco Resources' financial performance will exceed current levels. Delve into the full analysis health report here for a deeper understanding of Ramaco Resources.METC Discounted Cash Flow as at Mar 2026

Super Micro Computer

Overview: Super Micro Computer, Inc. develops and sells server and storage solutions based on modular and open-standard architecture globally, with a market cap of $13.19 billion.

Operations: The company generates revenue of $28.06 billion from its high-performance server solutions segment.

Estimated Discount To Fair Value: 41.6%

Super Micro Computer is trading at US$21.97, significantly below its estimated cash flow value of US$37.61, indicating potential undervaluation. Despite a volatile share price and recent legal challenges involving export violations, the company's earnings are projected to grow rapidly over the next three years. Super Micro's revenue growth forecast surpasses the U.S. market average, and it trades at a favorable value relative to peers, although profit margins have declined recently compared to last year.

The analysis detailed in our Super Micro Computer growth report hints at robust future financial performance. Navigate through the intricacies of Super Micro Computer with our comprehensive financial health report here.SMCI Discounted Cash Flow as at Mar 2026

Summing It All Up

Dive into all 155 of the Undervalued US Stocks Based On Cash Flows we have identified here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Searching for a Fresh Perspective?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GLNGMETC and SMCI.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Over the last 7 days, the United States market has experienced a 1.9% decline, yet it remains up by 15% over the past year with earnings projected to grow by 15% annually. In such conditions, identifying stocks that may be trading below their intrinsic value can present potential opportunities for investors seeking to capitalize on undervalued assets in a growing market.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Metropolitan Bank Holding (MCB) $80.65 $156.56 48.5% iRhythm Holdings (IRTC) $118.10 $230.91 48.9% Intapp (INTA) $24.68 $48.87 49.5% Hamilton Lane (HLNE) $94.77 $187.65 49.5% DNOW (DNOW) $12.25 $24.26 49.5% Crexendo (CXDO) $6.16 $11.90 48.2% Bridgewater Bancshares (BWB) $17.44 $33.82 48.4% Bar Harbor Bankshares (BHB) $31.81 $63.52 49.9% Alnylam Pharmaceuticals (ALNY) $317.36 $618.07 48.7% Alkami Technology (ALKT) $15.25 $30.05 49.2%

Click here to see the full list of 155 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's review some notable picks from our screened stocks.

Legence

Overview: Legence Corp. offers engineering, installation, and maintenance services for mission-critical systems in buildings across the United States, with a market cap of approximately $5.91 billion.

Operations: The company's revenue is primarily derived from its Engineering & Consulting segment, contributing $726.29 million, and its Installation & Maintenance segment, generating $1.82 billion.

Estimated Discount To Fair Value: 35.2%

Legence Corp. appears undervalued, trading at US$54.75, below its estimated future cash flow value of US$84.51. Despite recent net losses and goodwill impairments, revenue grew by 21.5% last year and is forecast to exceed US market growth at 18.2% annually. Earnings are expected to grow significantly by 83.31% per year as the company becomes profitable over the next three years, with revised guidance projecting revenues up to US$3.9 billion for 2026.

Our comprehensive growth report raises the possibility that Legence is poised for substantial financial growth. Navigate through the intricacies of Legence with our comprehensive financial health report here.LGN Discounted Cash Flow as at Mar 2026

Solstice Advanced Materials

Overview: Solstice Advanced Materials, Inc. is a specialty chemicals and advanced materials company with operations in the United States and internationally, boasting a market cap of $11.91 billion.

Operations: The company's revenue is derived from two main segments: Electronic & Specialty Materials, generating $1.10 billion, and Refrigerants & Applied Solutions, contributing $2.79 billion.

Story Continues

Estimated Discount To Fair Value: 43.2%

Solstice Advanced Materials trades at US$75.03, significantly below its future cash flow value of US$132.03, suggesting undervaluation. Despite a drop in profit margins from 15.8% to 6.1%, earnings are forecast to grow significantly by 21.3% annually, outpacing the broader market's growth rate of 15.5%. Recent expansion efforts include a major investment in ballistic fiber production and a licensing agreement with Hudson Technologies for refrigerant reclamation and resale, reinforcing its growth potential amidst financial challenges like high debt levels relative to operating cash flow.

Upon reviewing our latest growth report, Solstice Advanced Materials' projected financial performance appears quite optimistic. Click here and access our complete balance sheet health report to understand the dynamics of Solstice Advanced Materials.SOLS Discounted Cash Flow as at Mar 2026

AngloGold Ashanti

Overview: AngloGold Ashanti plc is a gold mining company with operations in Africa, Australia, and the Americas, and has a market cap of $45.08 billion.

Operations: The company's revenue is primarily derived from its Metals & Mining segment, specifically Gold & Other Precious Metals, totaling $9.89 billion.

Estimated Discount To Fair Value: 28.1%

AngloGold Ashanti trades at US$89.17, substantially below its estimated future cash flow value of US$124.1, highlighting potential undervaluation. Despite significant insider selling and an unstable dividend track record, earnings are projected to grow 16% annually, outpacing the US market's growth rate. Recent developments include the Arthur Gold Project in Nevada with robust economic prospects and a nine-year mine life, enhancing its cash flow potential amidst competitive cost structures and strategic expansions.

The analysis detailed in our AngloGold Ashanti growth report hints at robust future financial performance. Dive into the specifics of AngloGold Ashanti here with our thorough financial health report.AU Discounted Cash Flow as at Mar 2026

Seize The Opportunity

Dive into all 155 of the Undervalued US Stocks Based On Cash Flows we have identified here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Searching for a Fresh Perspective?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LGNSOLS and AU.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at patient monitoring stocks, starting with ResMed (NYSE:RMD).

Patient monitoring companies within the healthcare equipment industry offer devices and technologies that track chronic conditions and support real-time health management, such as continuous glucose monitors (CGMs) and sleep apnea machines. These businesses benefit from recurring revenue from consumables and software subscriptions tied to device sales (razor, razor blade model). The rising prevalence of chronic diseases like diabetes and respiratory disorders due to an aging population as well as growing adoption of digitization are good for the industry. However, these companies face challenges from high R&D costs and reliance on regulatory approvals. Looking ahead, the sector is positioned for growth due to tailwinds like the rising burden of chronic diseases from an aging population, the shift toward value-based care, and increased adoption of digital health solutions. Innovations in AI and machine learning are expected to enhance device accuracy and functionality, improving patient outcomes and driving demand. However, there are headwinds such as pricing pressures as healthcare costs are a key focus, especially in the US. An evolving regulatory landscape and competition from more tech-forward new entrants could present additional challenges.

The 4 patient monitoring stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 1.9% while next quarter’s revenue guidance was 1.9% below.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 11.4% since the latest earnings results.

ResMed (NYSE:RMD)

Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE:RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use.

ResMed reported revenues of $1.42 billion, up 11% year on year. This print exceeded analysts’ expectations by 1.6%. Overall, it was a strong quarter for the company with a decent beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

“Our second quarter results demonstrate the strength and resilience of our global business as we continue advancing our mission to help people sleep better, breathe better, and live longer and healthier lives in the comfort of their own home,” said Resmed’s Chairman and CEO, Mick Farrell.

Story Continues

ResMed Total Revenue

ResMed delivered the slowest revenue growth of the whole group. Unsurprisingly, the stock is down 12.1% since reporting and currently trades at $226.50.

We think ResMed is a good business, but is it a buy today? Read our full report here, it’s free.

Best Q4: iRhythm (NASDAQ:IRTC)

Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies (NASDAQ:IRTC) provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders.

iRhythm reported revenues of $208.9 million, up 27.1% year on year, outperforming analysts’ expectations by 3.4%. The business had a very strong quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ revenue estimates.iRhythm Total Revenue

iRhythm achieved the biggest analyst estimates beat and highest full-year guidance raise among its peers. Although it had a fine quarter compared its peers, the market seems unhappy with the results as the stock is down 23.3% since reporting. It currently trades at $121.81.

Is now the time to buy iRhythm? Access our full analysis of the earnings results here, it’s free.

DexCom (NASDAQ:DXCM)

Founded in 1999 and receiving its first FDA approval in 2006, DexCom (NASDAQ:DXCM) develops and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels without repeated finger pricks.

DexCom reported revenues of $1.26 billion, up 13.1% year on year, exceeding analysts’ expectations by 0.8%. Still, it was a mixed quarter as it posted full-year revenue guidance meeting analysts’ expectations.

DexCom delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. Interestingly, the stock is up 3% since the results and currently trades at $67.04.

Read our full analysis of DexCom’s results here.

Insulet (NASDAQ:PODD)

Revolutionizing diabetes care with its tubeless "Pod" technology, Insulet (NASDAQ:PODD) develops and manufactures innovative insulin delivery systems for people with diabetes, primarily through its Omnipod product line.

Insulet reported revenues of $783.8 million, up 31.2% year on year. This print topped analysts’ expectations by 2%. Overall, it was a strong quarter as it also produced a solid beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

Insulet pulled off the fastest revenue growth among its peers. The stock is down 13.1% since reporting and currently trades at $214.07.

Read our full, actionable report on Insulet here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

StockStory’s analyst team — all seasoned professional investors — uses quantitative analysis and automation to deliver market-beating insights faster and with higher quality.

View Comments